Novo Nordisk (ADR) (NVO)
Develops GLP-1 and insulin medicines for diabetes, obesity and rare diseases.
$39.78
vs last close−0.02 (−0.06%)
Something off on this page? Send us feedback.
Next report
Nov 4, 26
in 43 days
EPS estimate
$0.80
Revenue estimate
$11.22B
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$0.91$0.92$0.97$1.02$1.00$1.04$0.96Pending
Estimate$0.88$0.92$0.93$0.77$0.90$0.87$0.82$0.80
Surprise+3.4%0.0%+4.3%+32.5%+11.1%+19.5%+17.1%—
RevenueReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$11.86B$11.90B$11.97B$11.53B$12.50B$11.02B$12.13BPending
Estimate$11.55B$11.70B$11.92B$11.94B$12.13B$10.86B$10.89B$11.22B
Surprise+2.7%+1.7%+0.4%−3.5%+3.1%+1.5%+11.4%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | $4.61 | — | — |
| Sep 2027 | $5.05 | — | — |
| Jun 2027 | $5.08 | — | — |
| Mar 2027 | $5.54 | — | — |
| Dec 2026 | $4.47 | — | — |
| Nov 2026 | $0.80 | — | — |
| Aug 2026 | $0.82 | $0.96 | +17.1% |
| May 2026 | $0.87 | $1.04 | +19.5% |
| Feb 2026 | $0.90 | $1.00 | +11.1% |
| Nov 2025 | $0.77 | $1.02 | +32.5% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Jan 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| Apr 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Oct 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Oct 2016 | |||
| Aug 2016 | |||
| Apr 2016 | |||
| Feb 2016 | |||
| Oct 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | $4.61 | — | — | $76.21B | — | — | — |
| Sep 2027 | $5.05 | — | — | $72.78B | — | — | — |
| Jun 2027 | $5.08 | — | — | $73.16B | — | — | — |
| Mar 2027 | $5.54 | — | — | $71.49B | — | — | — |
| Dec 2026 | $4.47 | — | — | $75.29B | — | — | — |
| Nov 4, 2026 | $0.80 | — | — | $11.22B | — | — | — |
| Aug 5, 2026 | $0.82 | $0.96 | +17.1% | $10.89B | $12.13B | +11.4% | +0.6% |
| May 6, 2026 | $0.87 | $1.04 | +19.5% | $10.86B | $11.02B | +1.5% | +2.0% |
| Feb 3, 2026 | $0.90 | $1.00 | +11.1% | $12.13B | $12.50B | +3.1% | −14.6% |
| Nov 5, 2025 | $0.77 | $1.02 | +32.5% | $11.94B | $11.53B | −3.5% | +0.4% |
| Aug 6, 2025 | |||||||
| May 7, 2025 | |||||||
| Feb 5, 2025 | |||||||
| Nov 6, 2024 | |||||||
| Aug 7, 2024 | |||||||
| May 2, 2024 | |||||||
| Jan 31, 2024 | |||||||
| Nov 2, 2023 | |||||||
| Aug 10, 2023 | |||||||
| May 4, 2023 | |||||||
| Feb 1, 2023 | |||||||
| Nov 2, 2022 | |||||||
| Aug 3, 2022 | |||||||
| Apr 29, 2022 | |||||||
| Feb 2, 2022 | |||||||
| Nov 3, 2021 | |||||||
| Aug 4, 2021 | |||||||
| May 5, 2021 | |||||||
| Feb 3, 2021 | |||||||
| Oct 30, 2020 | |||||||
| Aug 6, 2020 | |||||||
| May 6, 2020 | |||||||
| Feb 5, 2020 | |||||||
| Nov 1, 2019 | |||||||
| Aug 20, 2019 | |||||||
| May 3, 2019 | |||||||
| Feb 1, 2019 | |||||||
| Nov 1, 2018 | |||||||
| Aug 8, 2018 | |||||||
| May 2, 2018 | |||||||
| Feb 1, 2018 | |||||||
| Nov 1, 2017 | |||||||
| Aug 10, 2017 | |||||||
| May 3, 2017 | |||||||
| Feb 2, 2017 | |||||||
| Oct 28, 2016 | |||||||
| Aug 5, 2016 | |||||||
| Apr 29, 2016 | |||||||
| Feb 3, 2016 | |||||||
| Oct 29, 2015 | |||||||
| Aug 6, 2015 |